Aminoglycoside-Induced Hearing Loss (AIHL) — Comprehensive Research Report

1. Disease Information

Overview. Aminoglycoside-induced hearing loss (AIHL) is a form of ototoxic, mitochondrially-mediated sensorineural hearing loss (SNHL) that occurs when a person carrying a pathogenic variant in the mitochondrial 12S rRNA gene MT-RNR1 is exposed to aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, streptomycin, kanamycin, neomycin). In susceptible individuals the hearing loss can be triggered by even a single, therapeutic-dose exposure and is typically bilateral, severe-to-profound, and irreversible. A separate, dose/duration-dependent form of ototoxicity also occurs in the general population (without a known MT-RNR1 variant) after cumulative or prolonged aminoglycoside courses, e.g., in cystic fibrosis (CF) or multidrug-resistant tuberculosis (MDR-TB) treatment.

Key identifiers: - OMIM: #580000 — DEAFNESS, AMINOGLYCOSIDE-INDUCED (OMIM.org) - Gene: MT-RNR1 (mitochondrial 12S rRNA), maternally inherited - GeneReviews: "Nonsyndromic Hearing Loss and Deafness, Mitochondrial" (PMID: 20301595) - ClinVar: RCV000010254/RCV000010255 (m.1555A>G); RCV001449811/RCV000010263 (m.1494C>T) - MeSH/ICD: classified under drug-induced/toxic sensorineural hearing loss (ICD-10 H91.0 Ototoxic hearing loss); MONDO term to be confirmed against the local MONDO release - Suggested MONDO search terms: "aminoglycoside-induced hearing loss," "aminoglycoside otototoxicity," "maternally inherited nonsyndromic hearing loss and deafness"

Synonyms: Aminoglycoside-induced deafness; maternally inherited aminoglycoside ototoxicity; MT-RNR1-related susceptibility to aminoglycoside ototoxicity; nonsyndromic mitochondrial deafness with aminoglycoside sensitivity.

Evidence base: Predominantly aggregated disease-level literature — pedigree studies of maternally-transmitted deafness (Prezant et al. 1993; Hutchin et al. 1993, foundational reports establishing MT-RNR1 m.1555A>G), population cohort studies (UK Biobank-linked cohort, PMID: 22223843), systematic reviews of ototoxicity in TB/CF populations, and structured pharmacogenomic guidance (CPIC). Individual EHR-level data exist mainly through CF and TB ototoxicity cohort studies.

2. Etiology

Disease Causal Factors

AIHL has two overlapping causal mechanisms: 1. Genetic (Mendelian/mitochondrial) susceptibility: A maternally inherited, usually homoplasmic, pathogenic variant in MT-RNR1 (12S rRNA) that structurally mimics bacterial 16S rRNA, allowing aminoglycosides to bind and disrupt mitochondrial ribosomal protein synthesis in cochlear hair cells upon drug exposure ("two-hit" gene-environment model). This is the classic Mendelian entry represented by OMIM #580000. 2. Non-genetic/dose-dependent ototoxicity: Cumulative aminoglycoside exposure (total dose, duration, peak/trough serum levels, concurrent nephrotoxicity) causes ototoxicity in genetically unselected patients, especially with repeated courses (CF, MDR-TB).

Genetic Risk Factors

• MT-RNR1 m.1555A>G — the most common and best-characterized variant; population prevalence ~1 in 500 (UK) to 0.19–1.8% globally, with marked founder-effect enrichment in some populations (e.g., 20.2% in Buryat individuals of the Baikal Lake region, PMID pending; PMC: 11222474). Penetrance of hearing loss with aminoglycoside exposure is considered near-100% for homoplasmic carriers.
• MT-RNR1 m.1494C>T — second most common variant, homoplasmic, reported in >20 Asian and 2 Spanish probands; average penetrance ~18% (range 0–77%) in the absence of documented aminoglycoside exposure, rising sharply with exposure.
• MT-RNR1 m.1095T>C — third variant flagged by CPIC as high-risk.
• Rarer variants at position 961 (961delT+Cn insertion, 961T>C) are also associated with nonsyndromic hearing loss with and without aminoglycoside exposure.
• Nuclear modifier genes: TRMU (mitochondrial tRNA-modifying enzyme; A10S missense variant) modulates penetrance of m.1555A>G/m.1494C>T-associated deafness in Arab-Israeli, European, and Chinese pedigrees. Secondary mitochondrial variants (e.g., m.4394C>T tRNA-Gln, m.1584A m62A rRNA methylation site) have also been proposed as penetrance modifiers (PMC: 9602358; HMG: 617880).

Environmental/Clinical Risk Factors

• Aminoglycoside class, dose, duration, and route (systemic vs. topical/otic) — cumulative dose is the dominant driver of non-genetic ototoxicity (CF cohorts: 4.5× higher odds of hearing loss with higher cumulative dosing).
• Renal impairment (reduced clearance → higher serum trough levels).
• Concurrent ototoxic drugs (loop diuretics, cisplatin/platinum chemotherapy, vancomycin).
• Advanced age, pre-existing renal or hepatic dysfunction, prolonged treatment duration (TB regimens of 6–12 months show near-universal hearing loss in some series).
• Noise exposure may synergize in genetically susceptible carriers even without drug exposure.

Protective Factors

• Absence of the MT-RNR1 risk variant (genotype-guided antibiotic selection).
• Use of alternative, non-ototoxic antimicrobials when genotype-positive.
• Emerging "designer aminoglycosides" engineered to spare the mitochondrial ribosome (see Treatment/Prevention, §12–13).
• Investigational otoprotectants (see below) — evidence base currently strongest for cisplatin, not aminoglycosides.

Gene-Environment Interaction

This is the defining feature of AIHL: the MT-RNR1 variant alone is often clinically silent (or produces only mild, late-onset, non-progressive/age-related hearing loss); the drug exposure is the "second hit" that converts genetic susceptibility into acute, severe, irreversible deafness. CPIC (2021, updated 2023) formalizes this as a pharmacogenomic gene-drug interaction (see §12).

3. Phenotypes

Quality of life impact: Profound bilateral SNHL in infancy/early childhood (the population most likely to receive gentamicin for suspected sepsis) has major, well-documented effects on language acquisition, education, and social development; adult-onset cases affect communication, employment, and mental health, consistent with general SNHL QoL literature (EQ-5D/SF-36 not disease-specific for AIHL).

4. Genetic/Molecular Information

Causal gene: MT-RNR1 (mitochondrially encoded 12S rRNA), OMIM *561000; the deafness phenotype is OMIM #580000.

Key pathogenic variants (all mitochondrial, maternally inherited): | Variant | Classification | Notes | |---|---|---| | m.1555A>G | Pathogenic (ClinVar RCV000010254/255) | Most common; homoplasmic; near-complete penetrance with aminoglycoside exposure; population frequency ~0.1–1.8% depending on cohort/region | | m.1494C>T | Pathogenic (ClinVar RCV001449811/RCV000010263) | Second most common; incomplete penetrance (avg. ~18%, up to 77% in some pedigrees) | | m.1095T>C | Pathogenic, CPIC-flagged | Rarer | | m.961delT+Cn / m.961T>C | Associated, variable evidence | Reported with and without aminoglycoside exposure | | m.7444G>A (MT-CO1) | Co-segregating secondary variant | Reported alongside m.1555A>G in a 3-generation Chinese family, may modify phenotype |

Zygosity/heteroplasmy: These variants are typically found in the homoplasmic state in affected pedigrees; CPIC (2021) explicitly states there is not yet sufficient evidence to define a heteroplasmy threshold below which aminoglycoside use is safe, so any detectable variant is treated per the homoplasmic guidance.

Functional consequence: Gain-of-susceptibility, not a classic loss-of-function — the base substitution creates a new base pair at the terminus of the penultimate stem of the 12S rRNA decoding site, structurally converting it toward the ancestral bacterial-type 16S rRNA conformation. This increases the aminoglycoside-binding pocket, permitting aminoglycoside binding to the mitochondrial ribosome much as it would bind a bacterial ribosome, inhibiting mitochondrial protein synthesis in cochlear tissue.

Modifier genes: - TRMU (mitochondrial tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase) — nuclear-encoded modifier; the A10S variant increases penetrance of MT-RNR1-associated deafness. - Secondary mtDNA variants (m.4394C>T tRNA-Gln, m.1584 12S rRNA methylation site) proposed as additional modifiers of clinical expressivity.

Population/allele frequency resources: gnomAD (mitochondrial variant server) and MITOMAP catalog m.1555A>G and m.1494C>T frequencies across populations; GeneReviews Table 2 provides population-stratified prevalence of m.1555A>G (NCBI Bookshelf NBK1422).

Suggested gene/molecular ontology bindings: HGNC gene symbol MT-RNR1 (mitochondrial, note standard HGNC/NCBI Gene entry applies; dismech convention uses lowercase hgnc: CURIEs for nuclear genes — MT-RNR1 is mitochondrially encoded and may require special handling per dismech's mitochondrial-gene conventions).

5. Environmental Information

• Primary environmental/pharmacologic trigger: Systemic aminoglycoside antibiotic exposure — gentamicin, tobramycin, amikacin, streptomycin, kanamycin, neomycin, and (in TB regimens) capreomycin/viomycin (technically cyclic peptides with similar ribosomal mechanism).
• Clinical contexts of exposure: Neonatal suspected sepsis (empiric gentamicin), CF pulmonary exacerbations (inhaled/IV tobramycin prophylaxis every 3–4 months), MDR-TB intensive-phase injectable regimens (kanamycin, amikacin, capreomycin), and historically streptomycin for various infections.
• Non-infectious environmental modifiers: Concurrent noise exposure may act synergistically with genetic susceptibility (reported in some m.1555A>G pedigrees even absent drug exposure) — supports possible G×E beyond drug exposure alone.
• No infectious-agent etiology — this is a drug-toxicity disorder, though the underlying illness prompting aminoglycoside use (sepsis, TB, CF pulmonary infection) is itself infectious in most cases; the ontology ECTO "aminoglycoside antibiotic exposure" or an equivalent drug-exposure term is the appropriate environmental/exposure binding, not a pathogen taxon.

6. Mechanism / Pathophysiology

Causal chain (genotype-positive form): 1. Trigger: Systemic aminoglycoside administration in a carrier of a pathogenic MT-RNR1 variant (m.1555A>G most common). 2. Molecular lesion: The variant reconfigures the 12S rRNA decoding-site conformation to resemble bacterial 16S rRNA, permitting high-affinity aminoglycoside binding within the mitochondrial ribosome's small subunit. 3. Mitochondrial protein synthesis inhibition: Aminoglycoside binding at the decoding site causes mistranslation/inhibition of mitochondrially-encoded OXPHOS subunit synthesis, analogous to bacterial ribosome inhibition. 4. Mitochondrial dysfunction in cochlear hair cells: Disrupted protein synthesis leads to impaired oxidative phosphorylation, mitochondrial membrane potential collapse, and generation of reactive oxygen species (ROS). 5. Downstream cell-death signaling: ROS and stress-kinase activation (notably c-Jun N-terminal kinase, JNK) amplify mitochondrial injury; cytochrome c release triggers caspase-9 → caspase-3 activation (intrinsic apoptotic pathway). Calcium flux from the endoplasmic reticulum via IP3 receptors into mitochondria is a key acute step (documented in zebrafish lateral-line hair cells). 6. Distinct temporal/mechanistic pathways by drug: Neomycin exposure causes rapid (within ~1h) hair cell death associated with acute mitochondrial calcium flux (attenuated by the mitochondria-targeted antioxidant mitoTEMPO); gentamicin causes delayed (up to 24h) hair cell death via calcium-independent pathways (PMC: 11602426). 7. Cell death mechanisms beyond classical apoptosis: Necroptosis has also been implicated alongside apoptosis in aminoglycoside- and cisplatin-induced ototoxicity; RIPOR2 translocation and phosphatidylserine externalization occur via mechanistically distinct pathways from canonical apoptosis (PMC: 12364911). 8. Anatomical gradient: Cochlear damage follows a base-to-apex gradient — basal-turn (high-frequency-encoding) outer hair cells are damaged first and are most vulnerable, explaining the characteristic high-frequency-first audiometric pattern; inner hair cells appear especially vulnerable at low, non-antibacterial concentrations relevant to hidden hearing loss. 9. Clinical manifestation: Irreversible bilateral sensorineural hearing loss, high-frequency-predominant progressing to lower frequencies, ± tinnitus and vestibulotoxicity.

Cellular processes involved: Mitochondrial protein synthesis inhibition (GO:0032543, mitochondrial translation), oxidative stress response (GO:0006979/0034599), intrinsic apoptotic signaling (GO:0097193), regulated necrosis/necroptosis, calcium-mediated signaling between ER and mitochondria.

Protein/molecular target: MT-RNR1 12S rRNA decoding site of the mitochondrial small ribosomal subunit (28S) — a structural/RNA target rather than a protein per se.

Cell types involved: Cochlear outer hair cells (basal turn preferentially) and inner hair cells, spiral ganglion neurons (secondary degeneration), vestibular hair cells (type I/II) for the vestibulotoxic phenotype.

Suggested ontology terms: - GO: GO:0032543 (mitochondrial translation), GO:0006915 (apoptotic process), GO:0070997 (neuron death), GO:0055074 (calcium ion homeostasis), GO:0034599 (cellular response to oxidative stress) - CL: CL:0000601 (outer hair cell), CL:0000598 (inner hair cell), CL:0000101 (sensory neuron; for spiral ganglion neurons), CL:0000211 (vestibular hair cell where applicable) - CHEBI: CHEBI:41000 (aminoglycoside antibiotic) or specific drugs — CHEBI:17833 (gentamicin), CHEBI:28864 (tobramycin), CHEBI:2637 (amikacin), CHEBI:9334 (streptomycin)

Molecular profiling data: Direct disease-specific transcriptomic/proteomic/metabolomic datasets in humans are limited (ototoxicity research relies heavily on animal/organoid models); zebrafish lateral-line and mouse cochlear explant transcriptomic studies of aminoglycoside exposure are available in GEO but are model-system, not human-tissue, datasets.

7. Anatomical Structures Affected

• Organ level: Inner ear (cochlea — primary; vestibular labyrinth — secondary/vestibulotoxicity). Systemic aminoglycoside toxicity also affects the kidney (nephrotoxicity) as a parallel, mechanistically related but anatomically distinct toxicity — relevant as a comorbid risk marker (nephrotoxicity often co-occurs and can indicate cumulative exposure).
• Tissue/cell level: Organ of Corti sensory epithelium — outer hair cells (basal turn first), inner hair cells, supporting cells (Deiters', pillar cells), spiral ganglion neurons (stria vascularis less directly implicated than in some other ototoxic mechanisms); vestibular sensory epithelium (crista ampullaris, maculae) hair cells for the vestibular phenotype.
• Subcellular level: Mitochondria (site of 12S rRNA target and ROS generation), endoplasmic reticulum (calcium release via IP3 receptors), cytosol (caspase cascade execution).
• Localization/laterality: Bilateral and typically symmetric.

Suggested UBERON terms: UBERON:0001846 (cochlea), UBERON:0005988 (organ of Corti), UBERON:0009663 (spiral ganglion), UBERON:0001824 (vestibular organ), UBERON:0000362 (mitochondrion is GO cellular component, not UBERON — use GO:0005739 for mitochondrion instead).

8. Temporal Development

• Onset: Can occur at any age when aminoglycoside is administered; clinically most consequential in neonates (empiric gentamicin for suspected sepsis) and in patients receiving prolonged/repeated courses (CF, MDR-TB). Onset relative to drug exposure is acute-to-subacute: earliest detectable ultra-high-frequency threshold shifts within hours (as early as 4h post-treatment in monitoring studies); clinically apparent hearing loss can appear within days to a few weeks of exposure.
• Progression: Once triggered, hearing loss is typically progressive over days to weeks, following a base-to-apex cochlear gradient (high frequencies affected first, then progressively lower/speech frequencies). It then stabilizes as permanent, non-progressive residual deafness once the ototoxic insult resolves (unlike some other genetic SNHL that continues to progress with age).
• Disease course pattern: Not relapsing-remitting — a single triggering exposure produces a step-wise, largely irreversible threshold shift. Genetically susceptible carriers not exposed to aminoglycosides may still show mild, later-onset, more gradual hearing decline in some pedigrees (independent low-penetrance expression), distinct from the acute triggered form.
• Critical windows for intervention: The period between first aminoglycoside dose and onset of measurable ototoxicity (hours to days) is the key window for early detection (serial high-frequency/ultra-high-frequency audiometry, otoacoustic emissions) and for genotype-based pre-exposure avoidance (point-of-care testing before/at time of first dose, see §10, §13).

9. Inheritance and Population

Inheritance pattern: Maternal (mitochondrial) inheritance — MT-RNR1 variants are transmitted exclusively through the maternal line; male carriers do not transmit the variant to offspring.

Penetrance: - m.1555A>G: near-complete (approaching 100%) for hearing loss when a homoplasmic carrier receives aminoglycosides; lower baseline penetrance without exposure, historically reported 28%, 20%, 15% across different pedigree analyses when aminoglycoside-induced cases are included/excluded. - m.1494C>T: average penetrance ~18% (range 0–77%) across families, strongly modified by aminoglycoside exposure history and by nuclear modifier genes (e.g., TRMU).

Expressivity: Variable — ranges from no detectable hearing loss (silent carriers without exposure) to profound congenital-onset deafness, influenced by modifier genes, heteroplasmy (where present), and environmental co-factors (noise, drug exposure).

Genetic anticipation: Not a recognized feature (this is not a repeat-expansion disorder).

Founder effects: Strong founder effect documented in the Buryat population of the Baikal Lake region of Russia (m.1555A>G prevalence 20.2% vs. 1.3% in surrounding Russian population) — PMC: 11222474 / Sci Rep s41598-024-66254-z. Founder enrichment also reported in some Spanish, Chinese, and Arab-Israeli pedigrees.

Carrier/population frequency: - UK general population: ~0.26% (~1 in 385–500) for m.1555A>G. - European general population: ~0.19%. - Global pooled estimate (enriched cohorts, hearing-loss-ascertained): ~1.8% (863/47,328) — likely an overestimate of true general-population frequency due to ascertainment bias. - Wide regional variation, up to 20%+ in isolated founder populations.

Population demographics: - No strong sex bias in mitochondrial transmission itself (both sexes can be affected equally since inheritance is maternal but penetrance is independent of the child's sex); clinical exposure risk (e.g., neonatal sepsis treatment) is population-wide. - Geographic/ethnic enrichment as above (Han Chinese, Spanish, Arab-Israeli, Buryat/Siberian populations disproportionately represented in the literature for specific variants). - Age distribution of clinical presentation skews toward populations with high aminoglycoside exposure: neonates (NICU sepsis treatment), children/young adults with CF, and TB patients of any age receiving injectable second-line regimens.

Epidemiology of ototoxicity in exposed populations (non-genotype-specific dose-dependent toxicity): - CF: prevalence of SNHL 0–57% depending on cohort/definition; 3–24% with <10 IV aminoglycoside doses, rising to 40–44% with >10 doses (recurrent exposure); cumulative dose associated with 4.5× higher odds of hearing loss; adult CF prevalence up to 59%. - TB: incidence ranges from 3.2% in early-phase standard therapy up to near-universal with prolonged (6–12 month) treatment; MDR-TB incidence of ototoxicity ~22.9% in one cohort; a meta-analysis found pooled prevalence of ototoxic hearing loss of ~40.6% across drugs, with kanamycin highest at ~49.65% (J Infect systematic review, PMID: 34015383).

10. Diagnostics

Clinical/audiologic tests: - Pure-tone audiometry (standard + extended high-frequency/ultra-high-frequency audiometry, which detects the earliest threshold shifts before speech-frequency involvement). - Otoacoustic emissions (OAEs, especially distortion-product OAEs) for early, pre-symptomatic monitoring, particularly in infants and non-verbal patients. - Serial audiometric monitoring protocols are standard of care during prolonged aminoglycoside courses (CF, TB) to detect ototoxicity early and allow dose adjustment/discontinuation. - Newborn hearing screening (universal newborn hearing screening programs) — m.1555A>G has been specifically studied as a risk factor for failed newborn hearing screening in preterm infant cohorts (PMC: 4236616).

Genetic testing: - Targeted MT-RNR1 variant testing (m.1555A>G, m.1494C>T, m.1095T>C at minimum, per CPIC) — via standard clinical mtDNA sequencing/genotyping panels or dedicated hearing-loss gene panels. - Rapid point-of-care genotyping: The Genedrive MT-RNR1 ID Kit provides m.1555A>G genotyping in ~26 minutes with reported 100% sensitivity/specificity in preclinical validation, enabling real-time avoidance of gentamicin in NICU settings before first dose (the PALOH trial, PMC: 8211036 and PMC: 8938898). Deployed at Manchester University NHS Foundation Trust and now expanding to 14 NHS neonatal units across England, Scotland, Wales, and Northern Ireland (2024–2025 rollout). - Non-invasive prenatal MT-RNR1 pharmacogenetic testing is under active investigation (2026 medRxiv preprint) as a means of identifying at-risk neonates before birth. - Whole mitochondrial genome sequencing can identify rarer/novel MT-RNR1 variants and co-segregating secondary mtDNA variants (e.g., m.7444G>A, m.4394C>T) beyond the three CPIC-actionable variants.

Clinical criteria / differential diagnosis: Diagnosis relies on temporal association between aminoglycoside exposure and new-onset bilateral high-frequency-predominant SNHL, ideally confirmed by pre/post-exposure audiometric comparison; differential diagnosis includes other causes of SNHL (congenital, noise-induced, presbycusis, other syndromic/nonsyndromic genetic deafness, autoimmune inner ear disease) which the genetic test and exposure history help exclude/confirm.

Screening: CPIC and NHS guidance effectively function as a pharmacogenomic screening recommendation — genotype before first aminoglycoside exposure wherever feasible (especially neonatal/NICU and CF/TB populations with anticipated repeated courses).

11. Outcome/Prognosis

• Reversibility: Hearing loss from AIHL, once established, is generally permanent and irreversible — this is a defining clinical feature distinguishing it from some other forms of drug ototoxicity.
• Severity spectrum: Ranges from mild high-frequency threshold shifts (often subclinical, detected only by extended high-frequency audiometry) to bilateral profound deafness.
• Functional/QoL impact: Congenital or early-childhood-onset profound deafness (as in genotype-positive neonates exposed to gentamicin) carries major lifelong implications for language development, education, and psychosocial functioning unless mitigated by early intervention (hearing aids, cochlear implantation, sign language/communication support).
• Complications: Concurrent vestibulotoxicity contributes to falls risk, gait instability, and oscillopsia, compounding functional impact, especially in adults.
• Mortality: Not directly disease-related; mortality risk in this population is driven by the underlying infection requiring aminoglycoside therapy (sepsis, MDR-TB), not by the ototoxicity itself.
• Prognostic factors: Genotype (homoplasmic MT-RNR1 pathogenic variant = near-certain severe outcome with exposure), cumulative dose, concurrent nephrotoxicity/renal impairment (reduces drug clearance, raising exposure), and early detection/discontinuation of the ototoxic agent.

12. Treatment

There is no reversal treatment for established AIHL; management is preventive (avoidance, monitoring, dose optimization) and rehabilitative once hearing loss has occurred.

Pharmacogenomics (CPIC): The Clinical Pharmacogenetics Implementation Consortium (CPIC) published a formal guideline in 2021 (updated March 2023) — cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1:

Any individual carrying the m.1555A>G, m.1494C>T, or m.1095T>C variant should avoid aminoglycoside antibiotics unless the risk of permanent hearing loss is outweighed by the severity of the infection and lack of suitable alternatives. No heteroplasmy threshold has been established as "safe," so any detectable variant is managed as if homoplasmic. The 2023 update also addressed whether variant carriers should avoid vaccines manufactured using aminoglycosides (residual amounts are not considered clinically significant for this indication).

Rehabilitative/supportive care (NCIT terms suggested): - Hearing aids — NCIT:C50384 (Hearing Aid) or device-category equivalent. - Cochlear implantation — NCIT term for cochlear implant procedure (surgical intervention; suggest NCIT:C61509 Cochlear Implant or closest available surgical-device term). - Speech-language therapy — NCIT:C15302 (Physical Therapy)-adjacent; NCIT speech therapy term if available. - Genetic counseling — NCIT:C15240 (Genetic Counseling), critical given maternal transmission implications for family planning. - Audiologic monitoring/surveillance — NCIT:C25218 category (Clinical Intervention or Procedure), specific monitoring/audiometry term.

Avoidance/substitution strategy (primary "treatment" for genotype-positive individuals): substitution of non-aminoglycoside antimicrobials for suspected sepsis/infection when clinically appropriate — NCIT:C15986 (Pharmacotherapy) with a different therapeutic_agent.

Experimental/otoprotective strategies (evidence base still developing for aminoglycosides specifically): - Sodium thiosulfate — FDA-, EMA-, and MHRA-approved (2022–2023) as an otoprotectant, but specifically for cisplatin-induced ototoxicity in pediatric localized non-metastatic solid tumors (SIOPEL6 and COG ACCL0431 trials showed reduced hearing-loss incidence: 39% vs 68%, and 44% vs 58%, respectively). Not yet an approved indication for aminoglycoside ototoxicity, though mechanistic overlap (oxidative stress, ROS scavenging) makes it of research interest. - Mitochondria-targeted antioxidants (e.g., mitoTEMPO) — shown in zebrafish models to attenuate acute neomycin-induced hair cell death via mitigation of mitochondrial calcium flux; not yet in human trials for AIHL. - N-acetylcysteine and related antioxidants — investigated in CF and other cohorts as adjunctive otoprotection during aminoglycoside courses; evidence remains preliminary/mixed.

Designer aminoglycosides in development (address root cause by decoupling antibacterial activity from mitochondrial ribosome binding): - Apramycin — a 4-monosubstituted 2-deoxystreptamine aminoglycoside shown in guinea pig and cochlear explant models to have substantially lower ototoxicity than gentamicin while retaining potent activity against MDR pathogens including Mycobacterium tuberculosis; structural studies (3.5 Å resolution apramycin-ribosome complexes) provide a framework for further reduced-toxicity aminoglycoside design (PNAS: 10.1073/pnas.1204073109; PMC: 3390888, 6382871). - Gentamicin C1a — a specific gentamicin congener also identified as having lower ototoxicity and no evidence of "hidden hearing loss" in guinea pig round-window application studies. - ELX-02 — a synthetic, eukaryotic-ribosome-selective aminoglycoside-class "read-through" agent developed primarily for nonsense-mutation genetic diseases (e.g., CF); engineered to eliminate antibacterial activity and reduce nephro-/ototoxicity. Phase 1 trials showed no severe ototoxicity or nephrotoxicity signals across dose range 0.3–7.5 mg/kg.

Experimental clinical trials: Multiple registered trials on ClinicalTrials.gov address sodium thiosulfate otoprotection (mostly cisplatin-focused; e.g., NCT05129748, NCT04541355) and ELX-02 pharmacokinetics/safety (NCT03776539, NCT03309605). No large registered trial currently targets otoprotection specifically for genotype-positive AIHL beyond the genotyping-avoidance strategy itself (PALOH and related implementation trials).

13. Prevention

AIHL is one of the clearest examples of a primary-prevention-focused pharmacogenomic disorder — because the hearing loss is irreversible once triggered, prevention (avoiding the triggering exposure in genetically susceptible individuals) is the dominant clinical strategy, more so than treatment.

• Primary prevention — genotype-guided prescribing: Pre-emptive or point-of-care MT-RNR1 genotyping before first aminoglycoside dose, especially in neonatal intensive care (NICU) settings where empiric gentamicin is common for suspected sepsis. The Manchester/NHS PALOH implementation trial demonstrated feasibility: 424/526 (80.6%) of eligible infants tested within the clinically actionable window using the Genedrive MT-RNR1 ID Kit (~26 min turnaround, 100% sensitivity/specificity in validation); identified variant carriers avoided aminoglycoside exposure entirely. This program is expanding to 14 NHS neonatal units UK-wide (2024–2025).
• Screening — high-risk/repeated-exposure populations: Consider MT-RNR1 genotyping before starting long-term/repeated aminoglycoside regimens in CF and MDR-TB patients, in addition to serial audiometric monitoring throughout treatment.
• Secondary prevention — early detection during ongoing therapy: Extended high-frequency/ultra-high-frequency audiometry and OAE monitoring at baseline and serially during aminoglycoside courses to detect subclinical threshold shifts before they progress into speech-frequency-affecting, functionally significant hearing loss; allows early drug discontinuation/dose adjustment.
• Tertiary prevention: Once hearing loss occurs, prompt referral to audiology/otolaryngology for hearing aid fitting or cochlear implant evaluation, and early educational/communication intervention in pediatric cases to mitigate developmental impact.
• Genetic counseling: Because inheritance is maternal, identification of an affected/carrier proband should prompt counseling and (ideally) cascade testing of maternal relatives, since all maternal-line relatives share the same variant and risk.
• Non-invasive prenatal testing (emerging, 2026): Under active investigation as a way to identify at-risk MT-RNR1-carrier neonates before birth, allowing avoidance planning before any postnatal antibiotic exposure decision is needed.
• Prescribing/stewardship policy: Clinical guideline bodies (CPIC; UK Genomics Education programs) now explicitly recommend genotype-informed antibiotic stewardship as formal policy, moving beyond individual clinician awareness to systematized point-of-care testing pathways.

14. Other Species / Natural Disease

• No well-established naturally-occurring veterinary counterpart of MT-RNR1-mediated AIHL has been prominently reported in the literature surveyed (OMIA search recommended for confirmation); aminoglycoside ototoxicity itself is a recognized general veterinary drug-toxicity concern (e.g., in companion animals receiving aminoglycosides), but genotype-linked susceptibility analogous to human MT-RNR1 variants is not established as a common veterinary syndrome in the sources reviewed here.
• The mitochondrial 12S rRNA target is deeply evolutionarily conserved (relationship to the bacterial 16S rRNA target is the entire basis of the mechanism), so cross-species susceptibility to aminoglycoside ototoxicity is a general pharmacological property of the drug class rather than being confined to genetically susceptible human carriers — this is why "designer aminoglycoside" research uses standard rodent (mouse, guinea pig) ototoxicity models even without introducing the human risk variant.
• Note: This report did not identify strong evidence of natural (spontaneous) veterinary MT-RNR1-variant disease; recommend an OMIA database check during KB curation to confirm absence/presence before asserting a definitive negative.

15. Model Organisms

• Zebrafish (lateral-line hair cells): Extensively used to dissect distinct temporal/mechanistic pathways of aminoglycoside-induced hair cell death — neomycin (rapid, ~1h, calcium-dependent via ER→mitochondria IP3-mediated calcium flux, rescued by mitoTEMPO) vs. gentamicin (delayed, up to 24h, calcium-independent) (PMC: 11602426, bioRxiv: 2024.05.30.596537). This model does not carry the human MT-RNR1 variant but demonstrates the general aminoglycoside-mitochondrial hair cell death mechanism and is used for mechanistic dissection and drug (designer-aminoglycoside/otoprotectant) screening.
• Guinea pig (cochlear explant / in vivo chronic ototoxicity model): Used to compare ototoxicity profiles across aminoglycoside congeners — demonstrated gentamicin C1a and apramycin as substantially less ototoxic than standard gentamicin via round-window drug application and compound action potential/outer hair cell survival assays (PMC: 6382871).
• Mouse (cochlear explants, in vivo dosing comparisons): Used to refine ototoxicity study protocols and compare different aminoglycoside dosing regimens in adult mice (Murillo-Cuesta et al., Lab Animals 2010).
• Genotype-specific (MT-RNR1 variant knock-in) models: This search did not surface a well-established, widely-cited mouse or zebrafish knock-in line carrying the human m.1555A>G or m.1494C>T variant that recapitulates genotype-specific hypersensitivity; most mechanistic model-organism work uses wild-type animals to study general aminoglycoside ototoxicity pathways rather than modeling the specific human genetic susceptibility variant. This is a notable gap worth flagging in a knowledge-gap/discussion entry — direct modeling of the human-specific MT-RNR1 gain-of-susceptibility mutation in an animal ribosome is complicated by sequence divergence between species' mitochondrial rRNA.
• Model limitations: Because the causal lesion is a single-nucleotide change in human mitochondrial 12S rRNA altering aminoglycoside binding affinity, and because most current animal ototoxicity models use wild-type (non-variant) rRNA, these models capture the general aminoglycoside-mitochondrial-ribosome-hair-cell-death mechanism well but do not directly recapitulate the human genotype-specific hypersusceptibility — this is a translational (human-model mismatch) gap appropriate for a HUMAN_MODEL_MISMATCH discussion entry in dismech curation, pending confirmation of whether a knock-in model has since been published.

Summary of Suggested Ontology Bindings for Curation

Key Caveats for Curators

1. Snippet/quote verification required: This report synthesizes web-search summaries and secondary source excerpts; per dismech's evidence policy, every claim used in a KB entry must be re-verified with an exact quoted substring from the actual cached reference (PMID/OMIM/GeneReviews/CPIC) via just fetch-reference, not from this report's paraphrased summaries.
2. CPIC guideline citation: Cite the primary CPIC publication (2021, PMID needed — search PubMed directly for the exact PMID of "Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype") plus its March 2023 update supplement.
3. MONDO ID and precise HPO/GO term matches should be confirmed against the locally cached ontology versions before binding, per dismech's anti-hallucination term-validation workflow.
4. Founder-effect prevalence figures (Buryat 20.2%, etc.) and global pooled prevalence (1.8%) should be sourced to their specific primary publications (Scientific Reports 2024, PMC:11222474) rather than cited from this summary.

Sources: - NC_012920.1(MT-RNR1):m.1555A>G AND Mitochondrial non-syndromic sensorineural hearing loss - ClinVar - NC_012920.1(MT-RNR1):m.1555A>G AND Aminoglycoside-induced deafness - ClinVar - Clinical Pharmacogenomic MT-RNR1 Screening for Aminoglycoside-Induced Ototoxicity and the Post-Test Counseling Conundrum - PubMed - Gentamicin Therapy and MT-RNR1 Genotype - Medical Genetics Summaries - NCBI Bookshelf - Non-invasive Prenatal MT-RNR1 Pharmacogenetic Testing for the Prevention of Aminoglycoside-Induced Profound Hearing Loss - medRxiv - Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection - PubMed - Multiple mechanisms of aminoglycoside ototoxicity are distinguished by subcellular localization of action - PMC - Towards the Prevention of Aminoglycoside-Related Hearing Loss - PMC - Mechanisms of Aminoglycoside- and Cisplatin-Induced Ototoxicity - American Journal of Audiology - Aminoglycoside induces RIPOR2 translocation and phosphatidylserine externalization via distinct mechanisms - PMC - Entry - #580000 - DEAFNESS, AMINOGLYCOSIDE-INDUCED - OMIM - Maternally inherited aminoglycoside-induced and nonsyndromic hearing loss is associated with the 12S rRNA C1494T mutation - PubMed - CPIC® Guideline for Aminoglycosides and MT-RNR1 - MT-RNR1 CPIC Guidelines - Aminoglycoside antibiotics — Genomics Education Knowledge Hub - New developments in aminoglycoside therapy and ototoxicity - PMC - Aminoglycoside- and glycopeptide-induced ototoxicity in children: a systematic review - PMC - Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review - PubMed - Nonsyndromic Hearing Loss and Deafness, Mitochondrial - PubMed (GeneReviews) - Mitochondrial tRNAGln 4394C>T Mutation May Contribute to the Clinical Expression of 1555A>G-Induced Deafness - PMC - Results: Patient with a known MT-RNR1 genotype requiring aminoglycoside antibiotics — In the Clinic - Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds - JCO - FDA Approves Sodium Thiosulfate to Decrease Cisplatin-Associated Ototoxicity - CancerNetwork - Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss - NEJM - New Rapid genomic testing at Manchester University NHS Foundation Trust prevents at-risk neonates from potential lifelong hearing loss - BioSpace - Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care - PubMed - Pharmacogenetics to Avoid Loss of Hearing (PALOH) trial protocol - PMC - Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care - PMC - Genotype testing to guide antibiotic use and prevent hearing loss - Scottish Health Technologies Group - Genetic test developed by Manchester researchers to prevent newborn babies going deaf, to be trialled across the UK - MFT NHS - Variant m.1555A>G in MT-RNR1 causes hearing loss and multiorgan mitochondrial disorder - PMC - High prevalence of m.1555A>G in patients with hearing loss in the Baikal Lake region of Russia as a result of founder effect - PMC / Scientific Reports - Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use - PMC - Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin - PNAS - ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease - Hearing in 44-45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study - PubMed - Table 2. Prevalence of MT-RNR1 Pathogenic Variant m.1555A>G by Population - GeneReviews, NCBI Bookshelf - Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants - PMC - Mitochondrial m.1584A 12S rRNA methylation in families with m.1555A>G associated hearing loss - Human Molecular Genetics

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.